An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms

Leukemia

Volumn 28, Issue 7, 2014, Pages 1407-1413

  Tefferi, A ^a   Thiele, J ^b   Vannucchi, A M ^c   Barbui, T ^d  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF COLOGNE   (Germany)

^c UNIVERSITY OF FLORENCE   (Italy)

^d PAPA GIOVANNI XXIII HOSPITAL   (Italy)

Author keywords

CALR; CSF3R; myeloproliferative; neutrophilic; WHO

Indexed keywords

BIOLOGICAL MARKER; CALRETICULIN; COLONY STIMULATING FACTOR 3 RECEPTOR; COLONY STIMULATING FACTOR RECEPTOR; JANUS KINASE 2; STEM CELL FACTOR RECEPTOR; UNCLASSIFIED DRUG;

BONE MARROW; CHRONIC MYELOID LEUKEMIA; CHRONIC NEUTROPHILIC LEUKEMIA; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; GENE MUTATION; HUMAN; MOLECULAR DIAGNOSIS; MYELOID METAPLASIA; MYELOPROLIFERATIVE NEOPLASM; POLYCYTHEMIA VERA; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; SYSTEMIC MASTOCYTOSIS; THROMBOCYTHEMIA; WORLD HEALTH ORGANIZATION;

BONE MARROW NEOPLASMS; CALRETICULIN; HUMANS; LEUKEMIA, NEUTROPHILIC, CHRONIC; MUTATION; MYELOPROLIFERATIVE DISORDERS; PRACTICE GUIDELINES AS TOPIC; PRIMARY MYELOFIBROSIS; RECEPTORS, COLONY-STIMULATING FACTOR; THROMBOCYTHEMIA, ESSENTIAL; WORLD HEALTH ORGANIZATION;

EID: 84904067758     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.35     Document Type: Review

References (39)

1. Swerdlow SHCE, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J et al. WHO Classification Of Tumours Of Haematopoietic And Lymhoid Tissues. IARC press Lyon, France, 2008.
2. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia rationale and important changes. Blood, 2009 114(5) 937-951.
3. Heller P, Kornblihtt LI, Cuello MT, Larripa I, Najfeld V, Molinas FC. BCR-ABL transcripts may be detected in essential thrombocythemia but lack clinical significance. Blood 2001 98 1990.
4. Pieri L, Spolverini A, Scappini B, Occhini U, Birtolo S, Bosi A et al. Concomitant occurrence of BCR-ABL and JAK2V617F mutation. Blood 2011 118 3445-3446.
5. Thiele J, Kvasnicka HM, Fischer R. Bone marrow histopathology in chronic myelogenous leukemia (CML)-evaluation of distinctive features with clinical impact. Histol Histopathol 1999 14 1241-1256.
6. Granger JM, Kontoyiannis DP. Etiology and outcome of extreme leukocytosis in 758 nonhematologic cancer patients a retrospective, single-institution study. Cancer 2009 115 3919-3923.
7. Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton MR et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. New Engl J Med 2007 356 459-468.
8. Tefferi A, Lasho TL, Abdel-Wahab O, Guglielmelli P, Patel J, Caramazza D et al. IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic-or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. Leukemia 2010 24 1302-1309.
9. Vannucchi AM, Lasho TL, Guglielmelli P, Biamonte F, Pardanani A, Pereira A et al. Mutations and prognosis in primary myelofibrosis. Leukemia 2013 27 1861-1869.
10. Rotunno G, Mannarelli C, Guglielmelli P, Pacilli A, Pancrazzi A, Pieri L et al. Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. Blood 2013 e-pub ahead of print 26 December 2013 doi10.1182/blood-2013-11-538983.
11. Tefferi A, Lasho TL, Finke CM, Knudson RA, Ketterling R, Hanson CH et al. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis clinical, cytogenetic and molecular comparisons. Leukemia 2014 28 1472-1477.
12. Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 2006 3 e270.
13. Pardanani AD, Levine RL, Lasho T, Pikman Y, Mesa RA, Wadleigh M et al. MPL515 mutations in myeloproliferative and other myeloid disorders a study of 1182 patients. Blood 2006 108 3472-3476.
14. Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. New Engl J Med 2013 369 2391-2405.
15. Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. New Engl J Med 2013 369 2379-2390.
16. Mesaeli N, Nakamura K, Zvaritch E, Dickie P, Dziak E, Krause KH et al. Calreticulin is essential for cardiac development. J Cell Biol 1999 144 857-868.
17. Rumi E, Pietra D, Ferretti V, Klampfl T, Harutyunyan AS, Milosevic JD et al. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood 2013 e-pub ahead of print 23 December 2013 doi10.1182/blood-2013-11-539098.
18. Chi J, Nicolaou KA, Nicolaidou V, Kouma L, Mitsidou A, Pierides C et al. Calreticulin exon 9 frameshift mutations in patients with thrombocytosis. Leukemia 2014 28 1129.
19. Vandenberghe P, Beel K. Severe congenital neutropenia, a genetically heterogeneous disease group with an increased risk of AML/MDS. Pediatr Rep 2011 3(Suppl 2) e9.
20. Germeshausen M, Ballmaier M, Welte K. Incidence of CSF3R mutations in severe congenital neutropenia and relevance for leukemogenesis Results of a long-term survey. Blood 2007 109 93-99.
21. Plo I, Zhang Y, Le Couedic JP, Nakatake M, Boulet JM, Itaya M et al. An activating mutation in the CSF3R gene induces a hereditary chronic neutrophilia. J Exp Med 2009 206 1701-1707.
22. Forbes LV, Gale RE, Pizzey A, Pouwels K, Nathwani A, Linch DC. An activating mutation in the transmembrane domain of the granulocyte colony-stimulating factor receptor in patients with acute myeloid leukemia. Oncogene 2002 21 5981-5989.
23. Beekman R, Valkhof MG, Sanders MA, van Strien PM, Haanstra JR, Broeders L et al. Sequential gain of mutations in severe congenital neutropenia progressing to acute myeloid leukemia. Blood 2012 119 5071-5077.
24. Maxson JE, Gotlib J, Pollyea DA, Fleischman AG, Agarwal A, Eide CA et al. Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML. New Engl J Med 2013 368 1781-1790.
25. Fleischman AG, Maxson JE, Luty SB, Agarwal A, Royer LR, Abel ML et al. The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition. Blood 2013 122 3628-3631.
26. Pardanani A, Lasho TL, Laborde RR, Elliott M, Hanson CA, Knudson RA et al. CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia. Leukemia 2013 27 1870-1873.
27. Beekman R, Valkhof M, van Strien P, Valk PJ, Touw IP. Prevalence of a new auto-activating colony stimulating factor 3 receptor mutation (CSF3R-T595I) in acute myeloid leukemia and severe congenital neutropenia. Haematologica 2013 98 e62-e63.
28. Kosmider O, Itzykson R, Chesnais V, Lasho T, Laborde R, Knudson R et al. Mutation of the colony-stimulating factor-3 receptor gene is a rare event with poor prognosis in chronic myelomonocytic leukemia. Leukemia 2013 27 1946-1949.
29. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005 434 1144-1148.
30. Pardanani A, Lasho TL, Finke C, Hanson CA, Tefferi A. Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera. Leukemia 2007 21 1960-1963.
31. Tefferi A, Rumi E, Finazzi G, Gisslinger H, Vannucchi AM, Rodeghiero F et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera an international study. Leukemia 2013 27 1874-1881.
32. Shih LY, Lee CT. Identification of masked polycythemia vera from patients with idiopathic marked thrombocytosis by endogenous erythroid colony assay. Blood 1994 83 744-748.
33. Barbui T, Thiele J, Gisslinger H, Finazzi G, Carobbio A, Rumi E et al. Masked polycythemia vera (mPV) results of an international study. Am J Hematol 2014 89 52-54.
34. Barbui T, Thiele J, Vannucchi AM, Tefferi A. Rethinking the diagnostic criteria of polycythemia vera. Leukemia 2014 28 1191-1195.
35. Marchioli R, Finazzi G, Specchia G, Cacciola R, Cavazzina R, Cilloni D et al. Cardiovascular events and intensity of treatment in polycythemia vera. New Engl J Med 2013 368 22-33.
36. Tefferi A, Barbui T. Personalized management of essential thrombocythemiaapplication of recent evidence to clinical practice. Leukemia 2013 27 1617-1620.
37. Elliott MA, Tefferi A. The molecular genetics of chronic neutrophilic leukaemia defining a new era in diagnosis and therapy. Curr Opin Hematol 2013 e-pub ahead of print 11 December 2013 doi10.1097/MOH.0000000000000014.
38. Bohm J, Schaefer HE. Chronic neutrophilic leukaemia 14 new cases of an uncommon myeloproliferative disease. J Clin Pathol 2002 55 862-864.
39. Engstrom PF, Bloom MG, Demetri GD, Febbo PG, Goeckeler W, Ladanyi M et al. NCCN molecular testing white paper effectiveness, efficiency, and reimbursement. J Natl Compr Canc Netw 2011 9(Suppl 6) S1-16.